Immunovant (IMVT) Short Interest Ratio & Short Volume $18.19 -1.25 (-6.43%) Closing price 04:00 PM EasternExtended Trading$18.79 +0.60 (+3.30%) As of 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immunovant Short Interest DataImmunovant (IMVT) has a short interest of 15.39 million shares, representing 22.19% of the float (the number of shares available for trading by the public). This marks a 4.06% increase in short interest from the previous month. The short interest ratio (days to cover) is 13.3, indicating that it would take 13.3 days of the average trading volume of 1.08 million shares to cover all short positions.Current Short Interest15,390,000 sharesPrevious Short Interest14,790,000 sharesChange Vs. Previous Month+4.06%Dollar Volume Sold Short$317.03 millionShort Interest Ratio13.3 Days to CoverLast Record DateFebruary 28, 2025Outstanding Shares169,861,000 sharesFloat Size69,350,000 sharesShort Percent of Float22.19%Today's Trading Volume2,468,525 sharesAverage Trading Volume1,080,148 sharesToday's Volume Vs. Average229% Short Selling Immunovant? Sign up to receive the latest short interest report for Immunovant and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIMVT Short Interest Over TimeIMVT Days to Cover Over TimeIMVT Percentage of Float Shorted Over Time Remove Ads Immunovant Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 2/28/202515,390,000 shares $317.03 million +4.1%22.2%13.3 $20.60 2/15/202514,790,000 shares $300.68 million +12.5%21.3%13.2 $20.33 1/31/202513,150,000 shares $285.88 million +2.5%19.2%11.7 $21.74 1/15/202512,830,000 shares $313.05 million +4.7%21.7%13.8 $24.40 12/31/202412,260,000 shares $303.68 million -2.9%19.7%14.6 $24.77 12/15/202412,630,000 shares $331.92 million -0.3%20.3%14.9 $26.28 11/30/202412,670,000 shares $357.29 million -2.7%20.4%15.2 $28.20 11/15/202413,020,000 shares $346.72 million -0.6%21.0%14.5 $26.63 10/31/202413,100,000 shares $383.31 million +1.3%21.1%15.6 $29.26 10/15/202412,930,000 shares $369.15 million +2.3%20.8%14.3 $28.55 Get the Latest News and Ratings for IMVT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter. 9/30/202412,640,000 shares $360.37 million +1.4%20.4%13.1 $28.51 9/15/202412,460,000 shares $369.69 million +0.6%20.1%11.9 $29.67 8/31/202412,390,000 shares $382.85 million +1.3%20.0%11.9 $30.90 8/15/202412,230,000 shares $377.66 million +9.1%19.8%10.6 $30.88 7/31/202411,210,000 shares $325.87 million +10.1%18.1%9.8 $29.07 7/15/202410,180,000 shares $310.59 million +1.6%16.5%8.9 $30.51 6/30/202410,020,000 shares $264.53 million -1.1%16.0%8.8 $26.40 6/15/202410,130,000 shares $263.38 million +10.0%16.4%8.9 $26.00 5/31/20249,210,000 shares $233.84 million -0.9%15.0%7.8 $25.39 5/15/20249,290,000 shares $287.34 million +3.7%15.3%8.7 $30.93 4/30/20248,960,000 shares $245.86 million +5.3%14.8%7.9 $27.44 4/15/20248,510,000 shares $259.30 million -5.7%14.1%7.4 $30.47 3/31/20249,020,000 shares $291.44 million -3.5%14.9%7.3 $32.31 3/15/20249,350,000 shares $285.46 million +7.7%15.3%7.1 $30.53 2/29/20248,680,000 shares $307.01 million -3.7%14.3%6.1 $35.37 2/15/20249,010,000 shares $340.58 million +8.4%14.8%6 $37.80 1/31/20248,310,000 shares $302.57 million +3.4%13.7%5.5 $36.41 1/15/20248,040,000 shares $340.57 million +7.8%13.3%5.1 $42.36 12/31/20237,460,000 shares $314.29 million -2.1%12.3%4.8 $42.13 12/15/20237,620,000 shares $325.68 million +10.6%12.6%3.1 $42.74 11/30/20236,890,000 shares $269.61 million -2.4%11.4%3.1 $39.13 11/15/20237,060,000 shares $241.73 million +5.5%11.6%3.3 $34.24 10/31/20236,690,000 shares $221.10 million -0.3%14.3%3 $33.05 10/15/20236,710,000 shares $251.02 million -8.0%14.3%3.2 $37.41 9/30/20237,290,000 shares $279.86 million +42.1%15.5%3.5 $38.39 9/15/20235,130,000 shares $111.89 million +4.7%9.7%4.6 $21.81 8/31/20234,900,000 shares $111.28 million +28.6%9.3%4.3 $22.71 8/15/20233,810,000 shares $78.18 million +2.7%7.3%3.4 $20.52 7/31/20233,710,000 shares $84.70 million +3.6%7.2%3.4 $22.83 7/15/20233,580,000 shares $74.25 million -2.7%6.9%3.2 $20.74A brutally honest economic warning for 2025 (see proof) (Ad)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....Full details here. 6/30/20233,680,000 shares $69.81 million +7.6%7.1%3.5 $18.97 6/15/20233,420,000 shares $72.26 million -0.3%6.6%3.2 $21.13 5/31/20233,430,000 shares $72.06 million -20.4%6.7%3.4 $21.01 5/15/20234,310,000 shares $79.35 million -4.9%8.4%4.6 $18.41 4/30/20234,530,000 shares $73.11 million -3.6%8.8%5.2 $16.14 4/15/20234,700,000 shares $67.07 million -3.5%9.2%5.5 $14.27 3/31/20234,870,000 shares $75.53 million +21.8%9.4%5.2 $15.51 3/15/20234,000,000 shares $61.64 million +16.6%7.6%3.9 $15.41 2/28/20233,430,000 shares $59.92 million +19.9%6.6%3.2 $17.47 2/15/20232,860,000 shares $51.85 million +23.3%5.5%2.6 $18.13 1/31/20232,320,000 shares $41.23 million -4.5%4.4%2 $17.77 1/15/20232,430,000 shares $45.20 million -32.5%4.7%2.1 $18.60 12/30/20223,600,000 shares $63.90 million +27.2%7.0%3.2 $17.75 12/15/20222,830,000 shares $43.04 million +8.0%5.5%2 $15.21 11/30/20222,620,000 shares $34.35 million -9.7%5.1%2.1 $13.11 11/15/20222,900,000 shares $38.54 million +7.8%5.6%2.6 $13.29 10/31/20222,690,000 shares $30.13 million -11.2%6.2%2.5 $11.20 10/15/20223,030,000 shares $27.85 million +6.3%7.0%3.2 $9.19 9/30/20222,850,000 shares $15.90 million +7.1%6.5%3.4 $5.58 9/15/20222,660,000 shares $13.51 million +56.5%6.7%7.8 $5.08 8/31/20221,700,000 shares $8.76 million +9.0%4.3%5 $5.15 8/15/20221,560,000 shares $8.05 million -4.9%3.8%4.6 $5.16 7/31/20221,640,000 shares $6.76 million -9.9%4.0%5.2 $4.12 7/15/20221,820,000 shares $7.90 million +1.1%4.4%5.4 $4.34 6/30/20221,800,000 shares $7.02 million -13.0%4.4%4.9 $3.90 6/15/20222,070,000 shares $7.14 million -10.4%5.0%5 $3.45 5/31/20222,310,000 shares $9.79 million +0.9%5.6%4.5 $4.24 5/15/20222,290,000 shares $9.25 million -8.8%5.5%4.3 $4.04 4/30/20222,510,000 shares $11.57 million +3.3%6.1%4.3 $4.61 4/15/20222,430,000 shares $12.15 million +5.2%5.9%3.9 $5.00 3/31/20222,310,000 shares $12.73 million -17.5%5.6%3.3 $5.51 3/15/20222,800,000 shares $14.76 million -3.1%6.8%4.1 $5.27 2/28/20222,890,000 shares $16.13 million +8.2%7.1%4.2 $5.58 2/15/20222,670,000 shares $15.27 million +1.1%6.6%3.7 $5.72 1/31/20222,640,000 shares $18.45 million +2.7%6.5%3.7 $6.99 1/15/20222,570,000 shares $20.20 million +11.3%N/A0 $7.86 12/31/20212,310,000 shares $19.68 million -28.3%5.7%3.6 $8.52 12/15/20213,220,000 shares $25.34 million -5.6%8.0%5.4 $7.87 11/30/20213,410,000 shares $26.26 million +3.0%8.4%6.7 $7.70 11/15/20213,310,000 shares $27.08 million -10.8%8.2%6.1 $8.18 10/29/20213,710,000 shares $29.83 million +4.2%9.2%5.9 $8.04 10/15/20213,560,000 shares $31.04 million -1.9%8.8%3.6 $8.72 9/30/20213,630,000 shares $31.54 million -15.2%9.0%3.5 $8.69 9/15/20214,280,000 shares $36.51 million -5.5%10.6%4.1 $8.53 8/31/20214,530,000 shares $39.23 million -11.5%11.2%4.2 $8.66 8/13/20215,120,000 shares $40.35 million +9.6%18.5%3.4 $7.88 7/30/20214,670,000 shares $48.85 million +2.2%20.5%3.2 $10.46 7/15/20214,570,000 shares $46.11 million -19.8%11.5%4 $10.09 6/30/20215,700,000 shares $60.25 million +6.0%14.3%5.2 $10.57 6/15/20215,380,000 shares $57.89 million -2.9%13.5%4.8 $10.76A brutally honest economic warning for 2025 (see proof) (Ad)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....Full details here. 5/28/20215,540,000 shares $83.99 million -13.7%13.9%4.8 $15.16 5/14/20216,420,000 shares $93.80 million +11.7%16.2%5.9 $14.61 4/30/20215,750,000 shares $93.73 million No Change14.2%4.3 $16.30 4/15/20215,750,000 shares $91.51 million -10.9%14.2%3.7 $15.92 3/31/20216,450,000 shares $96.75 million +41.1%15.9%4.1 $15.00 3/15/20214,570,000 shares $77.64 million +20.3%11.1%2.9 $16.99 2/26/20213,800,000 shares $60.57 million +12.4%9.2%2.7 $15.94 2/12/20213,380,000 shares $79.40 million +34.7%8.2%3.3 $23.49 1/29/20212,510,000 shares $98.44 million -1.6%6.2%3.3 $39.22 1/15/20212,550,000 shares $113.50 million -7.3%6.3%6.1 $44.51 12/31/20202,750,000 shares $135.66 million +118.3%6.8%6.7 $49.33 12/15/20201,260,000 shares $61.66 million -8.7%3.1%3 $48.94 11/30/20201,380,000 shares $68.77 million -28.1%3.4%3.2 $49.83 11/15/20201,920,000 shares $97.29 million -18.3%4.8%3.7 $50.67 10/30/20202,350,000 shares $100.93 million -7.1%7.7%4.4 $42.95 10/15/20202,530,000 shares $105.70 million +6.8%6.9%5 $41.78 9/30/20202,370,000 shares $83.40 million +52.9%6.4%5 $35.19 9/15/20201,550,000 shares $59.95 million +31.4%4.5%3 $38.68 8/31/20201,180,000 shares $40.07 million +26.9%3.5%2.2 $33.96 8/14/2020929,700 shares $25.40 million -13.9%2.7%2 $27.32 7/31/20201,080,000 shares $24.42 million -8.5%3.1%2.5 $22.61 7/15/20201,180,000 shares $28.54 million -11.9%3.4%2.8 $24.19 6/30/20201,340,000 shares $32.63 million +205.7%5.8%3 $24.35 6/15/2020438,300 shares $11.23 million -57.5%2.4%1.2 $25.63 5/29/20201,030,000 shares $26.43 million -24.3%5.5%3.9 $25.66 5/15/20201,360,000 shares $26.33 million -11.7%7.3%5.9 $19.36 4/30/20201,540,000 shares $28.58 million +32.8%5.6%8.2 $18.56 4/15/20201,160,000 shares $20.89 million +72.5%6.0%7 $18.01 3/31/2020672,400 shares $12.78 million -17.4%3.8%4.9 $19.01 IMVT Short Interest - Frequently Asked Questions What is Immunovant's current short interest? Short interest is the volume of Immunovant shares that have been sold short but have not yet been covered or closed out. As of February 28th, investors have sold 15,390,000 shares of IMVT short. 22.19% of Immunovant's shares are currently sold short. Learn More on Immunovant's current short interest. What is a good short interest ratio for Immunovant? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMVT shares currently have a short interest ratio of 13.0. Learn More on Immunovant's short interest ratio. Which institutional investors are shorting Immunovant? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Immunovant: Wolverine Trading LLC, Troluce Capital Advisors LLC, Group One Trading LLC, Caption Management LLC, Citadel Advisors LLC, Jane Street Group LLC, Susquehanna International Group LLP, Concourse Financial Group Securities Inc., Barclays PLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Immunovant? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 22.19% of Immunovant's floating shares are currently sold short. Is Immunovant's short interest increasing or decreasing? Immunovant saw a increase in short interest during the month of February. As of February 28th, there was short interest totaling 15,390,000 shares, an increase of 4.1% from the previous total of 14,790,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Immunovant's float size? Immunovant currently has issued a total of 169,861,000 shares. Some of Immunovant's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Immunovant currently has a public float of 69,350,000 shares. How does Immunovant's short interest compare to its competitors? 22.19% of Immunovant's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Immunovant: Moderna, Inc. (13.19%), Viatris Inc. (2.30%), Dr. Reddy's Laboratories Limited (2.23%), Ascendis Pharma A/S (10.93%), Sarepta Therapeutics, Inc. (5.74%), Vaxcyte, Inc. (10.21%), Qiagen (1.23%), Roivant Sciences Ltd. (10.42%), Revolution Medicines, Inc. (10.24%), Lantheus Holdings, Inc. (9.53%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($23.74 billion), iShares 20+ Year Treasury Bond ETF ($10.75 billion), MicroStrategy Incorporated ($6.56 billion), Apollo Global Management, Inc. ($5.40 billion), Charter Communications, Inc. ($4.57 billion), AppLovin Co. ($4.45 billion), Capital One Financial Co. ($4.33 billion), Super Micro Computer, Inc. ($4.23 billion), Schlumberger Limited ($3.22 billion), and Royal Caribbean Cruises Ltd. ($3.06 billion). View all of the most shorted stocks. What does it mean to sell short Immunovant stock? Short selling IMVT is an investing strategy that aims to generate trading profit from Immunovant as its price is falling. IMVT shares are trading down $1.25 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Immunovant? A short squeeze for Immunovant occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMVT, which in turn drives the price of the stock up even further. How often is Immunovant's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMVT, twice per month. The most recent reporting period available is February, 28 2025. More Short Interest Resources from MarketBeat Related Companies Moderna Short Interest Data Viatris Short Interest Data Dr. Reddy's Laboratories Short Interest Data Ascendis Pharma A/S Short Interest Data Sarepta Therapeutics Short Interest Data Vaxcyte Short Interest Data Qiagen Short Interest Data Roivant Sciences Short Interest Data Revolution Medicines Short Interest Data Lantheus Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IMVT) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IMVT Stock Free IMVT Stock Alerts